Navigation Links
Fero Industries Expands Sucanon® Distribution in Mexico
Date:7/13/2011

CALGARY, Alberta, July 13, 2011 /PRNewswire/ -- Fero Industries, Inc. (OTCQB: FROI) (the "Company") is pleased to report that Merck S.A. de C.V. has successfully expanded Sucanon® retail distribution throughout Mexico from 900 points-of-sale to over 2,500 outlets and pharmacy chains. Sucanon® is available over-the-counter in Mexico from many well-known retailers including WalMart Supercenters, Superama, Farmacias del Ahorro, Comercial Mexicana, Farmacias Guadalajara, Soriana, Farmacias San Pablo, and Gusher Farmacias.

"Due to the excellent performance of Merck S.A. de C.V. as our business partners, Sucanon® is well positioned on the most important retail shelves throughout Mexico," said Mr. Luis M. Lopez, Chief Operating Officer of Fero Industries Inc. and President of Pharmaroth S.A., the Company's Mexican subsidiary. "This rapid expansion of distribution has placed Sucanon® and Sucanon® related marketing material in almost three times as many retail stores and should continue to boost market awareness and acceptance of Sucanon® as an over-the-counter treatment for type-2 diabetes across Mexico."

Sucanon® is approved as an over-the-counter ("OTC") remedy for type-2 diabetes by regulatory authorities in Mexico and is distributed there under an exclusive agreement with Merck S.A. de C.V. (Merck S.A. de C.V. is the Mexico and Latin America sales and marketing organization of German pharmaceutical and chemical giant, Merck KGaA.)

Commercial sales of Sucanon® began in January 2011 in Mexico. Mexico has one of the largest and fastest growing diabetic populations in the world, estimated at 15% of the total population. This indicates over 16 million diagnosed cases of diabetes, up seven fold since 1990. Diabetes is now the leading cause of death in Mexico and costs the country more than one-third of its total public health care budget annually.

About Sucanon®

Sucanon® is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called "insulin sensitizers". Pre-clinical and clinical studies show that Sucanon® and other insulin sensitizers lower a patient's blood sugar by increasing the muscle, fat and liver's sensitivity to the body's own naturally produced insulin. Sucanon® has been approved for prescription sale in China and Peru. Sucanon® is also approved as an OTC treatment for type-2 diabetes by regulatory authorities in Mexico, and is distributed there under an exclusive agreement with Merck S.A. de C.V.

For further information regarding Sucanon®, please visit the Fero Industries Inc. website at www.feroindustries.com, email us at info@feroindustries.com, or call toll-free (855) 543-4900.

About Fero Industries Inc.

Fero Industries, Inc. (OTCQB: FROI) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for type-2 diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. Fero's strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.

For investor relations contact:
Michael Irving
Paramount Advisors, LLC
(407) 878-5462

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Fero Industries, Inc. (the Company) to be materially different from those expressed or implied by such forward-looking statements.

The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov under "Search for Company Filings".


'/>"/>
SOURCE Fero Industries, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ansell Limited Acquires Sandel Medical Industries LLC, an Innovator in Surgical Safety Solutions
2. Healthmark Industries Honored With Two Awards
3. Winner Industries (Shenzhen) Nominated for WOW Innovation Award(TM)
4. Roper Industries to Acquire Northern Digital, Inc.
5. Roper Industries Announces Record First Quarter Results
6. Roper Industries Reschedules First Quarter 2011 Financial Results Conference Call
7. The Procter & Gamble Company and Teva Pharmaceutical Industries Form Consumer Health Care Partnership
8. Applied Precision Exhibit at the Biophysical Society Annual Meeting Showcases New Microscopy Solutions for Life Science Industries
9. Roper Industries Announces Senior Subordinated Convertible Notes Due 2034 to Accrue Contingent Cash Interest
10. Reportlinker Adds Teva Pharma. Industries Ltd: PharmaVitae Profile
11. FDA Launches Website To Help Regulated Industries Save Time, Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... report published by Allied Market Research titled, "World ... and Forecasts, 2014-2020", estimates the world synthetic biology ... synthesis and sequencing technology segment would continue to ... software tools segment, collectively, held around half of ...
(Date:2/5/2016)... N.C. , Feb. 5, 2016  Despite the ... been slower than other industries to embrace Big Data ... with utilization. On the medical side, organizations have begun ... everything from clinical trials to adherence. ... from benchmarking firm Best Practices, LLC, Big Data has ...
(Date:2/5/2016)... 5, 2016  Syneron Medical Ltd. (NASDAQ: ... announced today that William Griffing , Chief ... scheduled to participate in the Leerink Partners 5 ... 11, 2016 in New York City ... to meet with the Mr. Griffing and will ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... 08, 2016 , ... GrassrootsHealth published data from its D*action ... diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than a ... health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of ...
(Date:2/8/2016)... ... 08, 2016 , ... The schedule is now online for the ... Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues ... and causes of chronic illness in children. , Very recent articles have cited 1 ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
Breaking Medicine News(10 mins):